The FDA has granted Fast Track Designation to AKY-1189 (actinium-225; 225 Ac) a potent alpha-emitting radioisotope in the ...
National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50; Many respondents report undergoing ...
Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or metastatic carcinoma ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.
Dr. Aleksander Słusarczyk presented the clinical case of a 75-year-old woman who presented with a two-month history of hematuria. Her medical history was notable for diabetes, prior myocardial ...
In this study, researchers sought to determine whether HER2-targeted therapies, including disitamab vedotin, have clinical utility in pretreated, HER2-positive, locally advanced unresectable or ...
FDA fast track enables increased FDA-company interactions and potential rolling BLA submission to accelerate development for serious diseases with unmet need. AKY-1189 uses a miniprotein ...
The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
IBRX stock surge has pushed valuation to ~33x sales as Anktiva adoption accelerates - but the premium assumes flawless ...
Somatic pathogenic genomic alterations in patients with SCBC, UC, and SCLC of any stage who underwent blood- or tissue-based genomic profiling through the Tempus assay were cataloged. Baseline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results